Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 Biomarker phenotype BEFREE First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors. 31822497 2020
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 Biomarker phenotype BEFREE We determined antitumor activity, safety, and pharmacokinetics of the small-molecule MET inhibitor AMG 337 in <i>MET</i>-amplified G/GEJ/E adenocarcinoma or other solid tumors.<b>Patients and Methods:</b> In this phase II, single-arm study, adults with <i>MET</i>-amplified G/GEJ/E adenocarcinoma (cohort 1) or other <i>MET</i>-amplified solid tumors (cohort 2) received AMG 337 300 mg/day orally in 28-day cycles. 30366938 2019
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 Biomarker phenotype BEFREE MET amplification is a frequently observed genomic aberration in solid tumors. 30695737 2019
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 AlteredExpression phenotype BEFREE When aberrantly activated, MET and its stroma-secreted ligand HGF (Hepatocyte Growth Factor) concur to tumor onset, progression, and metastasis in solid tumors, thus representing a relevant target for cancer precision medicine. 30544501 2018
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 AlteredExpression phenotype BEFREE Cabozantinib is a tyrosine kinase inhibitor with activity against vascular endothelial growth factor receptor 2 (VEGFR2) and MET that has demonstrated clinical activity in advanced solid tumors. 29016998 2018
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 Biomarker phenotype BEFREE To evaluate the safety (including adverse events and dose-limiting toxicities [DLTs]), tolerability, pharmacokinetics and antitumor activity of the investigational MET inhibitor rilotumumab alone in patients with advanced solid tumors (Part 1) or in combination with cisplatin plus capecitabine (CX) in patients with MET-positive advanced gastric or gastroesophageal junction cancer (Part 2). 28973403 2017
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 Biomarker phenotype BEFREE AMG 337, a selective small-molecule MET inhibitor, was evaluated in Asian patients with advanced solid tumors. 28582510 2017
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 Biomarker phenotype BEFREE Silk-elastinlike protein polymer (SELP) hydrogels were used for matrix-mediated delivery of oncolytic Ad, containing short hairpin RNA (shRNA) targeted to C-Met (sh-C-Met), to solid tumors in a nude mouse model of human head and neck cancer. 24962819 2015
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 Biomarker phenotype BEFREE A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. 26155941 2015
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 AlteredExpression phenotype BEFREE Recently, activation of the c-MET/hepatocyte growth factor signaling pathway was associated with poor prognosis in various solid tumors and was one of the mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib. 24827412 2014
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 Biomarker phenotype BEFREE MET amplification was detected in 2.6% of patients with solid tumors and was associated with adenocarcinomas, high-grade histology, and higher metastatic burden. 25326232 2014
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 Biomarker phenotype BEFREE Tyrosine kinase inhibitors (TKIs) targeted to MET are undergoing clinical trials in patients with solid tumors, but the precise mechanism of the antitumor activity of these drugs remains unclear. 21716144 2011
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 AlteredExpression phenotype BEFREE Met protein is a tyrosine kinase receptor for hepatocyte growth factor (HGF). c-Met has morphogenic, mitogenic, and motogenic properties and is overexpressed in many solid tumors. 11369990 2001
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 Biomarker phenotype BEFREE Summarizing these and previous results, mutations of the MET proto-oncogene were detected in 17/129 sporadic papillary renal carcinomas but not in other solid tumors. 10327054 1999
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 AlteredExpression phenotype BEFREE The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. 1917129 1991